However, GBM patients are refractory to current immunotherapies assessing nivolumab, an anti-programmed cell death protein 1 (anti–PD-1) therapy, alone or in combination with radiotherapy and temozolomide (6, 23). This evidence concerns the gene PDCD1 and glioblastoma.